Mitoxantrone versus doxorubicin in advanced breast cancer: a randomized cross-over trial.
D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001769:Blood / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007364:Intercalating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D008942:Mitoxantrone; D011897:Random Allocation; D013997:Time Factors
D000880:Anthraquinones; D000970:Antineoplastic Agents; D007364:Intercalating Agents; D004317:Doxorubicin; D008942:Mitoxantrone